Biogen cut at Jefferies as 2025 has a tough setup

FRBRX Fund  USD 147.44  1.08  0.74%   
Slightly above 53% of Franklin Biotechnology's investor base is interested to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are impartial at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
  
Jefferies downgraded Biogen from a Buy to Hold on monday, citing a challenging outlook for 2025. Analysts highlighted that Biogens Alzheimers drug, Leqembi, faces slower-than-expected growth, with Jefferies lowering its 2025 sales estimates to 466 million, below the consensus of 494 million. We move to HOLD as 2025 has a tough setup modest Leqembi and Skyclarys US , and real need for more pipeline and serious BD to get investors re-engaged, said Jefferies.

Read at finance.yahoo.com
Yahoo News
  

Franklin Biotechnology Fundamental Analysis

We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Franklin Biotechnology is currently under evaluation in probability of bankruptcy among similar funds. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Franklin Biotechnology Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.

Other Information on Investing in Franklin Mutual Fund

Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories